- Details
- Description
-
Packaging Size60T/bottle
-
Strength50mg&150mg
-
CompositonTucatinib
-
TreatmentHER2+ metastatic breast cancer
-
FormTablet
-
BrandPHOTUCA
-
Quantity Unit50mg&150mg*50T/Bottle
-
ManufacturerPHOKHAM 2 PHARMACEUTICAL,LAOs PDR
Tucatinib is a kinase inhibitor used to treat certain types of unresectable/metastatic HER-2 positive breast cancer.The recommended dose is 300 mg tucatinib (two 150 mg tablets) taken twice daily continuously in combination with trastuzumab and capecitabine.